<DOC>
	<DOCNO>NCT01588548</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability AZD 1208 maximum tolerate dose ( MTD ) define dose ( ) clinical evaluation give daily patient advance solid malignancy include malignant lymphoma</brief_summary>
	<brief_title>Global Phase1 Study Assess Safety Tolerability AZD1208 Advanced Solid Tumors Malignant Lymphoma</brief_title>
	<detailed_description>A Phase I , Open-Label , Multicentre Study Assess Safety , Tolerability , Pharmacokinetics Preliminary Anti-tumour Activity Ascending Doses AZD1208 Patients Advanced Solid Malignancies include Malignant Lymphoma</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients sign Written Informed Consent Form full explanation participation study Patients age 18 year old Patients diagnose solid malignant tumour malignant lymphoma refractory standard therapy standard therapy exist Patients good physical condition ( walk look ) within last 2 week . Patients least one lesion accurately assess Patients recently receive receiving prohibit medication treatment Patients unresolved side effect previous treatment Patients spinal cord compression brain metastases Patients severe systemic disease ( e.g. , uncontrolled hypertension , hepatitis B , hepatitis C human immunodeficiency virus [ HIV ] infection ) Patients significant abnormal ECG finding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Advanced solid malignancy</keyword>
	<keyword>Malignant lymphoma</keyword>
</DOC>